Cyanoacrylate applications in the GI tract

Cameron, Rees; Binmoeller, Kenneth F.

doi:10.1016/j.gie.2013.01.028

Cited by 34 publications

(29 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When administered by a suitably experienced endoscopist for hemostasis, cyanoacrylate glue is considered a safe, inexpensive and effective salvage alternative to surgery when other measures have failed or if selective transarterial embolization is unavailable[19-21,31]. It is important to note that several different formulations of cyanoacrylate glue are available; these different formulations merit investigation as they may lead significantly different results and safety profiles.…”

Section: Discussionmentioning

confidence: 99%

Non-variceal upper gastrointestinal bleeding: Rescue treatment with a modified cyanoacrylate

Grassia¹,

Capone²,

Iiritano³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo evaluate the safety and efficacy of a modified cyanoacrylate [N-butyl-2-cyanoacrylate associated with methacryloxysulfolane (NBCA + MS)] to treat non-variceal upper gastrointestinal bleeding (NV-UGIB).METHODSIn our retrospective study we took into account 579 out of 1177 patients receiving endoscopic treatment for NV-UGIB admitted to our institution from 2008 to 2015; the remaining 598 patients were treated with other treatments. Initial hemostasis was not achieved in 45 of 579 patients; early rebleeding occurred in 12 of 579 patients. Thirty-three patients were treated with modified cyanoacrylate: 27 patients had duodenal, gastric or anastomotic ulcers, 3 had post-mucosectomy bleeding, 2 had Dieulafoy’s lesions, and 1 had duodenal diverticular bleeding.RESULTSOf the 45 patients treated endoscopically without initial hemostasis or with early rebleeding, 33 (76.7%) were treated with modified cyanoacrylate glue, 16 (37.2%) underwent surgery, and 3 (7.0%) were treated with selective transarterial embolization. The mean age of patients treated with NBCA + MS (23 males and 10 females) was 74.5 years. Modified cyanoacrylate was used in 24 patients during the first endoscopy and in 9 patients experiencing rebleeding. Overall, hemostasis was achieved in 26 of 33 patients (78.8%): 19 out of 24 (79.2%) during the first endoscopy and in 7 out of 9 (77.8%) among early rebleeders. Two patients (22.2%) not responding to cyanoacrylate treatment were treated with surgery or transarterial embolization. One patient had early rebleeding after treatment with cyanoacrylate. No late rebleeding during the follow-up or complications related to the glue injection were recorded.CONCLUSIONModified cyanoacrylate solved definitively NV-UGIB after failure of conventional treatment. Some reported life-threatening adverse events with other formulations, advise to use it as last option.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-variceal upper gastrointestinal bleeding: Rescue treatment with a modified cyanoacrylate

Grassia¹,

Capone²,

Iiritano³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…reported carrying out EUS‐EIS into the feeding veins connected with esophageal varices. Cameron and Binmoeller described the experience of carrying out EUS‐CA on esophageal varices. However, we have to conclude that the clinical application of EUS‐EIS to esophageal varices can be extremely limited in clinical settings because conventional endoscopic treatments such as EIS and EVL have achieved high success rates of esophageal variceal eradication and sclerosant injection into the feeding vein carries the risk of leakage into the greater circulatory system including such as the heart or lungs.…”

Section: Discussionmentioning

confidence: 99%

“…In their procedure, after visualizing the gastric varices from the esophagus through the diaphragmatic crus muscle under EUS guidance, a saline solution‐primed 19‐gauge FNA needle was inserted through the distal esophageal wall and diaphragm muscle directly into the gastric varices (Fig. ) . Then, coils were deployed and injection of 1 mL of an undiluted ocrilate CA (2‐octyl‐cyanoacrylate; Dermabond (Johnson & Johnson, New Brunswick, USA)) solution was done, followed by 1 mL saline flushing into the needle lumen to prevent CA occlusion (Fig.…”

Section: Interventional Eus In the Treatment Of Gastric Varicesmentioning

confidence: 99%

“…Then, coils were deployed and injection of 1 mL of an undiluted ocrilate CA (2‐octyl‐cyanoacrylate; Dermabond (Johnson & Johnson, New Brunswick, USA)) solution was done, followed by 1 mL saline flushing into the needle lumen to prevent CA occlusion (Fig. ) . This procedure was repeated immediately as needed until the varices were obliterated.…”

Section: Interventional Eus In the Treatment Of Gastric Varicesmentioning

confidence: 99%

See 1 more Smart Citation

Potential application of interventional endoscopic ultrasonography for the treatment of esophageal and gastric varices

Hikichi

Obara

Nakamura

et al. 2015

Digestive Endoscopy

View full text Add to dashboard Cite

Interventional endoscopic ultrasonography (EUS) has been developed mainly for the treatment of pancreaticobiliary disorders (e.g. cyst drainage for pancreatic pseudocysts, biliary drainage for malignant biliary obstruction, and celiac plexus neurolysis). Recently, the application of interventional EUS has been expanded to a new field, the treatment of gastrointestinal varices. There have been several studies examining this new technique for the treatment of esophageal and gastric varices. In the present review, we have summarized the current status of interventional EUS for the treatment of esophageal and gastric varices (e.g. EUS-guided coil deployment for gastric varices) and clarified the clinical feasibility of this procedure.

show abstract

“…Management options until recently have been limited to medical therapy, esophageal dilatation or surgical repair, with variable results . Histoacryl (N‐butyl‐2‐cyanoacrylate, Braun Dexon GmbH, Spangenberg, Germany) is a tissue glue that has recently been successfully used in the management of a variety of luminal fistulas . In our patient, we performed endoscopic closure of esophagogastric fistula with Argon Plasma Coagulation ablation of the tract followed by injection of 2 mL Histoacryl (Fig B).…”

mentioning

confidence: 99%